DOJ Reschedules Certain Marijuana Products to Schedule III: What Operators Need to Know 

On April 22, 2026, the U.S. Department of Justice (DOJ), through the Drug Enforcement Administration (DEA), issued a final order rescheduling certain marijuana-related products from Schedule I to Schedule III of the federal Controlled Substances Act (CSA). While this action is limited in scope, it carries significant regulatory and federal tax implications, particularly for state-licensed medical marijuana businesses and companies with FDA-approved cannabis-derived products. This is a meaningful step toward federal normalization of medical marijuana, but it is not decriminalization, and it does not remove marijuana from Schedule I in all circumstances.

Federal Tax Implications: Section 280E

The most immediate financial impact of this rescheduling is on federal taxes.

State-licensed medical marijuana businesses are no longer subject to Internal Revenue Code Section 280E, which disallows ordinary and necessary business deductions for companies trafficking in Schedule I or II controlled substances. This represents a material change to federal taxable income calculations and may allow businesses to deduct operating expenses such as rent, payroll and marketing while achieving significantly lower effective federal tax rates.

The DOJ noted that this rule does not itself determine federal tax liability, and businesses should consult with their tax advisors regarding implementation and timing. The DOJ also encouraged the Treasury Department to consider retrospective relief, though no automatic retroactive relief is granted under this order.

Regulatory Impact on Operators

FDA-Approved Product Manufacturers and Distributors: Entities handling marijuana exclusively in FDA-approved drug products must now comply with Schedule III requirements, including DEA registration, prescription and dispensing controls, and recordkeeping, security, labeling, and inventory rules.
State-Licensed Medical Marijuana Operators: The DEA has established a new expedited federal registration pathway for state-licensed medical marijuana manufacturers, distributors, and dispensers. Under this framework, state licenses serve as conclusive evidence of state authorization, federal oversight is streamlined and coordinated with existing state regulatory systems, and DEA registration is automatically suspended if the underlying state license lapses.
This cooperative federal-state regulatory approach reflects a significant shift in how the federal government engages with state-licensed medical marijuana markets, without constituting full federal legalization.

How Withum Can Help

Withum’s Cannabis Services Team is actively assisting clients with 280E transition modeling and planning, evaluation of federal-state compliance obligations and structuring considerations following Schedule III placement. We will continue monitoring the situation as the DOJ issues further guidance.